Syra Health Corp. (SYRA), a healthcare technology firm, on Thursday announced the pricing of a public offering of 3.203 million class A shares and warrants.This will allow the company to offer up to 3.203 million class A shares and series B warrants to purchase up to 3.203 class A shares at a combined price of $0.64 per share and accompanying warrants.

医疗保健技术公司Syra Health Corp.（Syra）周四宣布公开发行320.3万股a类股票和认股权证的定价。这将允许该公司以每股0.64美元的合并价格发行至多320.3万股A类股和B系列认股权证，以购买至多320.3股A类股和附带认股权证。

The series warrants will have an exercise price of $0.64 per share and will be exercisable immediately upon issuance. The series A warrants will expire 18 months post-issuance and the series B warrants will expire on the fifth anniversary of the issuance. The aggregate gross proceeds to the company from the offering are expected to be approximately $2.1 million.

该系列认股权证的行权价格为每股0.64美元，可在发行后立即行权。A系列认股权证将在发行后18个月到期，B系列认股权证将在发行五周年时到期。本次发行给公司的总收益预计约为210万美元。

.

.

The company expects potential additional gross proceeds of $4.1 million from the series warrants, if fully exercised on a cash basis.The closing of the offering is expected to occur on or about September 13. Syra Health intends to use the net proceeds from the offering for marketing, sales, application development, research and development, general corporate, and other purposes.

该公司预计，如果在现金基础上完全行权，该系列认股权证可能会产生410万美元的额外总收益。此次发行预计将于9月13日左右结束。Syra Health打算将此次发售的净收益用于营销、销售、应用程序开发、研究与开发、一般公司和其他目的。

SYRA was trading down by 49 percent at $0.408 in the pre-market trade on the Nasdaq. For comments and feedback contact: editorial@rttnews.comBusiness News.

在纳斯达克市场前交易中，SYRA下跌49%，收于0.408美元。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股